|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ӲƤ�� |
|
����ģ�� |
|
����ù�� |
| ��������������� | |
|
��Ԫ������ |
|
����Ӣ��У |
| PubMed | |
|
Article by ��Ԫ������ |
|
Article by ����Ӣ��У |
�ò���ù�ؽ���ӲƤ������ģ�ͼ���Ӧ��
��Ԫ������1, ����Ӣ��У2
1. �й�ҽѧ��ѧԺƤ�����о���;
2. �й�Э��ҽ�ƴ�ѧƤ�����о���
ӲƤ����һ�ֿ��ۼ�������ٺ������Ľ����֯��,��ȷ�еIJ���ͷ��������в���ȫ���,Ŀǰ�������������ҩ��ͷ������������ʵ�ӲƤ���Ķ���ģ��,���ڲ����������ƺ���ѡ����ҩ����зdz���Ҫ�����塣���о�Ӧ�ò���ù��ע��ʵ����,����ӲƤ������ģ�ͼ���Ӧ��������˹��ɡ�
1. �й�ҽѧ��ѧԺƤ�����о���;
2. �й�Э��ҽ�ƴ�ѧƤ�����о���
1. �й�ҽѧ��ѧԺƤ�����о���;
2. �й�Э��ҽ�ƴ�ѧƤ�����о���
[2] Fisman S,Russo GG.The toxic pseudosclerodermas.Int J Derrmatol,1991,30(12):837-842.
[3] Varga J,Jimenez SA.Chemical exposure-induced cutaneous fibrosis.ArchDermatol,1994,130(1):97-100.
[4] Yamamoto T,Takagawa S,Katayama I,et al.Animal model of sclerotic skin.��:Local injections of bleomycin induce sclerotic skin mimicking scleroderma.J Invest Dermatol,1999,112:456-462.
[5] Yamamoto T.Takagawa S,Katayama I,et al.Anti-sclerotic effect oftransforming growth factor-�� antibody in a mousee model of bleomycin induced scleroderma.Clin Immunol,1999,92(1):6-13.
[6] Hunzelmann N,Anders S.Fierllbeck G,et al.Multicenter trial of 1 yearof treatment with recombinant interferon gamma.Arch Dermatol,1997,133(5):609-613.
[7] Yamamoto T,Takagawa S,Kuroda M,et al.Effect of interferon-ron exper-imental scleroderma induced by bleomycin.Arch Dermatol,2000,292:362-365.
[8] Black CM,Silman A J,Herrick AI,et al.Interferon-�� does not improveoutcome at one year in patients with diffuse cutaneous scleroderma..Arthri-tis Rheum,1999,42:299-305.
[9] Boeder WA,Noble NA.Transforming growth factor ��in tissue fibrosis.N Engl J Med,1994,331(19):1286-1292.
[10] Peltonen J,Kahari L,Jaakkola S,et al.Evaluation of transforming growth facter �� and type �� procollagen gene expression in fibrotic skin dieases by situ hybridization.J Invest Dermatol,1990,94(3):365-371.
[11] Denis M.Neutralization of transforming growth factor-��l in a mouse modelof immune-induced lung fibrosis.Immunology,1994,82(4):584-590.
[12] McCormick LL,Zhang Y,Tootell E,et al.Anti-TGF-��treatment preventsskin and lung fibrosis in murine sclerodermatous graft-versus-host disease:a model for human scleroderma.J Immunol,1999,163(10):5693-.5699.
[13] Murrel DF.A radical proposal for the pathogenesis of scleroderma.J AmAcad Dermatol,1993,28(1):78-84.
[14] Sambo P,Jannino L,Candela M,et al.Monecytes of patients wito sys-temic sclerosis (scleroderma) spontaneously release in vitro increasedamounts of superoxide anion.J Invest Dematol,1999,112(1):78-85.
[15] Yamamoto T,Takagawa S,Katayama I,et al.Effect of superoxide dis-mutasa on bleomycin-induced dermal sclerosis:Implications for the treat-ment of systemic sclerosis.J Invest Dematol,1999,113:843-847.